we will see, but I suspect there will be a lot of disappointed investors here with these pie-in-the-sky valuations.
Throw in RA approval in GB
So, your saying on UK approval alone, NW Bio will be worth $30-35B? I dont think so. Those are Alzheimer's and other CNS valuations based on large populations that need the drug, not GBM. No offense but I think you need to go back to the drawing board throwing around these types on valuations for GBM approval in UK.